These Are the Top Pediatric Care Providers in Westchester

Image
vaccine finder near me :: Article Creator Where Can I Find The New COVID Vaccine Near Me? - KQED Where Can I Find the New COVID Vaccine Near Me?KQEDKQEDSave ArticleKQEDKQED News News Daily Newsletter Stay on top of what's happening in the Bay Area with essential Bay Area news stories, sent to your inbox every weekday. Podcasts & Radio Hyphenación Where conversation and cultura meet. Video & TV Meredith's Must-Sees See Senior Director of TV Programming Meredith Speight's recommendations from this month's KQED 9, PLUS and Passport schedules. Events Videos from KQED Live Watch recordings of recent KQED Live events. Support KQED Donor-Advised Funds Support KQED by using your donor-advised fund to make a charitable gift. Featured ...

nOPV2M4a Polio Vaccine — Precision Vaccinations - PrecisionVaccinations

nOPV2M4a Polio Vaccine Description

nOPV2M4a Polio Vaccine candidate is derived from the live, infectious virus — but this time it has been ‘triple-locked’ using genetic engineering, to prevent it from becoming harmful. 

nOPV2M4a is genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence.

nOPV2M4a Polio Vaccine Indication

nOPV2M4a Polio Vaccine is indicated to prevent circulating vaccine-derived polio-virus (cVDPV) polio cases.

Most cases of cVDPV are caused by mutations in a strain of poliovirus called type 2.

nOPV2M4a Polio Vaccine News

October 29, 2020 - New polio vaccine which is designed to prevent harmful mutations poised to get emergency WHO approval

July 13, 2019 - The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

nOPV2M4a Polio Vaccine Clinical Studies

Clinical Trial NCT04544787: A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates

  • The Phase 2 study is designed to evaluate the safety and immunogenicity of both nOPV2 vaccines in adults before testing in young children and then infants.
  • The primary objectives of the Phase 2 study include the general safety and immunogenicity of the two candidate vaccines, primarily based on comparison with historical data obtained in the Phase 4 study of Sabin mOPV2 for OPV-vaccinated subjects, in order to establish non-inferior immunogenicity and acceptable safety profile.
  • Assessment of the general safety of the 2 candidate vaccines in IPV-only vaccinated subjects will be based on comparison with data from a placebo group

Clinical Trial NCT03430349: Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in IPV Primed Adults (nOPV2M4a)

  • This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding and genetic stability of both nOPV2 vaccine candidates in IPV-primed adults before testing in a larger adult and adolescent (> 15 y of age) population, and then in young children and infants.
  • The primary objectives of the subsequent Phase 1 and 2 studies will include the general safety, the shedding and genetic stability of the two candidate vaccines, primarily based on comparison with historical data obtained in the Phase 4 studies of Sabin mOPV2.


Comments

Popular posts from this blog

Primary Care - North Greece Internal Medicine & Pediatrics

180+ chief medical officers to know | 2025

Screening and Testing for Hepatitis B Virus Infection ...